Co-CEO David Lazar Discloses 98% Beneficial Ownership Following $6M Preferred Stock Conversion
INDP sits 38% above its 52-week low of $1.52.
Summary
Co-CEO David Lazar has disclosed beneficial ownership of 98% of Indaptus Therapeutics' common stock after converting $6 million in preferred shares, marking a near-complete change of control and significant dilution.
Key Events · Ownership and Investor Activity · INDP
-
Co-CEO Acquires 98% Stake
David E. Lazar, the company's Co-Chief Executive Officer and Chairman, now beneficially owns approximately 111 million shares, representing 98% of the common stock.
-
Conversion of $6 Million Preferred Stock
This ownership stems from the conversion of Series AA and AAA Convertible Preferred Stock, acquired for a total of $6 million, following shareholder approval on February 26, 2026.
-
Effective Change of Control
The transaction fundamentally alters the company's ownership structure, placing nearly all control with a single individual who also holds key executive and board positions.
-
Extreme Dilution for Existing Shareholders
While providing capital, the conversion results in overwhelming dilution for pre-existing common stockholders.
Analysis · INDP · Life Sciences
This Schedule 13D filing confirms a near-complete change of control for Indaptus Therapeutics. David E. Lazar, who was appointed Co-Chief Executive Officer and Chairman, now beneficially owns approximately 98% of the company's common stock following the conversion of $6 million in Series AA and AAA Convertible Preferred Stock. This massive acquisition of shares, which was approved by shareholders on February 26, 2026, injects critical capital into the company but results in extreme dilution for existing shareholders, fundamentally altering the ownership structure and investment thesis. Lazar's stated belief that the shares were undervalued suggests a strategic long-term play, but the immediate impact on minority shareholders is highly negative due to the overwhelming dilution.
At the time of this filing, INDP was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $1.52 to $47.60. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.